Ranbaxy kicking biosimilars business into high gear
The chief executive of Ranbaxy Laboratories said the company will launch at least three new biosimilar medicines in India by 2015, mostly to treat cancer, and needs to develop such high-tech medicines to remain a serious player in the global generics business.
Like this story, share it with millions of investors on M3
Ranbaxy kicking biosimilars business into high gear
The chief executive of Ranbaxy Laboratories said the company will launch at least three new biosimilar medicines in India by 2015, mostly to treat cancer, and needs to develop such high-tech medicines to remain a serious player in the global generics business.
Like this story, share it with millions of investors on M3
Ranbaxy kicking biosimilars business into high gear
The chief executive of Ranbaxy Laboratories said the company will launch at least three new biosimilar medicines in India by 2015, mostly to treat cancer, and needs to develop such high-tech medicines to remain a serious player in the global generics business.
The chief executive of Ranbaxy Laboratories said the company will launch at least three new biosimilar medicines in India by 2015, mostly to treat cancer, and needs to develop such high-tech medicines to remain a serious player in the global generics business.
Arun Sawhney said Ranbaxy, which is majority owned by Japanese drugmaker Daiichi Sankyo, will introduce a cancer treatment in India next year and then follow up with launches of at least two other biosimilars in the same market over the following year or two.
